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Dapivirine Intravaginal Rings for 
Prevention of HIV Transmission
? Dapivirine (NNRTI) IVRs were used for 28 days by 
healthy, HIV-negative women 18-35 yrs
? Adverse events possibly related were similar in 
dapivirine and placebo IVR groups
? No clinically relevant changes from baseline
? Drug was effectively distributed throughout genital 
tract (cervicovaginal fluids) at concentrations 104-fold 
(reservoir) to 106-fold (matrix) greater than EC90 (0.9ng/mL)
? Terminal half-life in vaginal fluids was 15-16 hrs
? Systemic exposure to dapivirine was low            
(Cmax 1.21 ng/mL for matrix and 0.05 ng/mL for reservoir)
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Conclusions – Discussion Points
? Dapivirine IVRs were safe and well 
tolerated for 28 days in HIV-negative 
women
? Matrix rings deliver the highest dose in 
tissues
? Pharmacokinetic data support future 
development as monthly-dosed microbicide
? Microbicide use is female controlled
? Monthly replacement of IVR may increase 
product adherence and efficacy
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